(SGRY) Surgery Partners - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US86881A1007
Stock: Surgery Centers, Hospitals, Emergency, Anesthesia, Urgent Care
Total Rating 23
Risk 69
Buy Signal -1.16
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 49.6% |
| Relative Tail Risk | -14.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.33 |
| Alpha | -59.50 |
| Character TTM | |
|---|---|
| Beta | 0.691 |
| Beta Downside | 0.935 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.22% |
| CAGR/Max DD | -0.38 |
Description: SGRY Surgery Partners January 10, 2026
Surgery Partners, Inc. (NASDAQ:SGRY) owns and operates a nationwide network of ambulatory surgery centers, surgical hospitals, and ancillary services such as urgent-care clinics, multi-specialty physician practices, and anesthesia groups. Its facilities focus on non-emergency procedures across orthopedics, pain management, ophthalmology, gastroenterology, and general surgery, while also offering emergency department capabilities.
Key operational metrics as of the most recent quarter include approximately 140 facilities with an average occupancy rate of 78 % and a year-over-year revenue growth of roughly 9 %, driven by the broader industry shift toward outpatient care and favorable payer reimbursement trends. The company’s EBITDA margin has stabilized near 23 %, reflecting efficient cost management in a sector where labor and supply-chain pressures remain material cost drivers.
For a deeper quantitative view, see ValueRay’s detailed SGRY financial dashboard.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -171.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.27 > 1.0 |
| NWC/Revenue: 15.70% < 20% (prev 15.43%; Δ 0.27% < -1%) |
| CFO/TA 0.04 > 3% & CFO 282.3m > Net Income -171.4m |
| Net Debt (3.67b) to EBITDA (816.6m): 4.49 < 3 |
| Current Ratio: 1.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (126.9m) vs 12m ago 0.60% < -2% |
| Gross Margin: 23.92% > 18% (prev 0.24%; Δ 2368 % > 0.5%) |
| Asset Turnover: 42.48% > 50% (prev 39.62%; Δ 2.86% > 0%) |
| Interest Coverage Ratio: 1.29 > 6 (EBITDA TTM 816.6m / Interest Expense TTM 518.1m) |
Altman Z'' 0.48
| A: 0.06 (Total Current Assets 1.10b - Total Current Liabilities 586.0m) / Total Assets 7.95b |
| B: -0.10 (Retained Earnings -800.2m / Total Assets 7.95b) |
| C: 0.09 (EBIT TTM 666.6m / Avg Total Assets 7.74b) |
| D: -0.19 (Book Value of Equity -813.3m / Total Liabilities 4.39b) |
| Altman-Z'' Score: 0.48 = B |
Beneish M -3.06
| DSRI: 0.97 (Receivables 579.3m/542.9m, Revenue 3.29b/2.99b) |
| GMI: 0.99 (GM 23.92% / 23.64%) |
| AQI: 0.99 (AQ_t 0.68 / AQ_t-1 0.69) |
| SGI: 1.10 (Revenue 3.29b / 2.99b) |
| TATA: -0.06 (NI -171.4m - CFO 282.3m) / TA 7.95b) |
| Beneish M-Score: -3.06 (Cap -4..+1) = AA |
What is the price of SGRY shares?
As of February 08, 2026, the stock is trading at USD 13.56 with a total of 1,225,827 shares traded.
Over the past week, the price has changed by -8.75%, over one month by -13.08%, over three months by -37.25% and over the past year by -47.13%.
Over the past week, the price has changed by -8.75%, over one month by -13.08%, over three months by -37.25% and over the past year by -47.13%.
Is SGRY a buy, sell or hold?
Surgery Partners has received a consensus analysts rating of 4.42.
Therefore, it is recommended to buy SGRY.
- StrongBuy: 8
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SGRY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25.5 | 87.7% |
| Analysts Target Price | 25.5 | 87.7% |
| ValueRay Target Price | 10 | -26% |
SGRY Fundamental Data Overview February 03, 2026
P/E Forward = 17.0648
P/S = 0.5845
P/B = 1.0829
P/EG = 1.66
Revenue TTM = 3.29b USD
EBIT TTM = 666.6m USD
EBITDA TTM = 816.6m USD
Long Term Debt = 3.46b USD (from longTermDebt, last quarter)
Short Term Debt = 144.3m USD (from shortTermDebt, last quarter)
Debt = 3.87b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.67b USD (from netDebt column, last quarter)
Enterprise Value = 5.59b USD (1.92b + Debt 3.87b - CCE 203.4m)
Interest Coverage Ratio = 1.29 (Ebit TTM 666.6m / Interest Expense TTM 518.1m)
EV/FCF = 28.80x (Enterprise Value 5.59b / FCF TTM 194.1m)
FCF Yield = 3.47% (FCF TTM 194.1m / Enterprise Value 5.59b)
FCF Margin = 5.90% (FCF TTM 194.1m / Revenue TTM 3.29b)
Net Margin = -5.21% (Net Income TTM -171.4m / Revenue TTM 3.29b)
Gross Margin = 23.92% ((Revenue TTM 3.29b - Cost of Revenue TTM 2.50b) / Revenue TTM)
Gross Margin QoQ = 23.77% (prev 23.67%)
Tobins Q-Ratio = 0.70 (Enterprise Value 5.59b / Total Assets 7.95b)
Interest Expense / Debt = 8.66% (Interest Expense 335.1m / Debt 3.87b)
Taxrate = 17.86% (5.50m / 30.8m)
NOPAT = 547.6m (EBIT 666.6m * (1 - 17.86%))
Current Ratio = 1.88 (Total Current Assets 1.10b / Total Current Liabilities 586.0m)
Debt / Equity = 2.24 (Debt 3.87b / totalStockholderEquity, last quarter 1.73b)
Debt / EBITDA = 4.49 (Net Debt 3.67b / EBITDA 816.6m)
Debt / FCF = 18.90 (Net Debt 3.67b / FCF TTM 194.1m)
Total Stockholder Equity = 1.75b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.21% (Net Income -171.4m / Total Assets 7.95b)
RoE = -9.78% (Net Income TTM -171.4m / Total Stockholder Equity 1.75b)
RoCE = 12.79% (EBIT 666.6m / Capital Employed (Equity 1.75b + L.T.Debt 3.46b))
RoIC = 10.40% (NOPAT 547.6m / Invested Capital 5.27b)
WACC = 7.56% (E(1.92b)/V(5.79b) * Re(8.46%) + D(3.87b)/V(5.79b) * Rd(8.66%) * (1-Tc(0.18)))
Discount Rate = 8.46% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.46%
[DCF Debug] Terminal Value 82.19% ; FCFF base≈181.8m ; Y1≈215.4m ; Y5≈334.1m
Fair Price DCF = 19.87 (EV 6.24b - Net Debt 3.67b = Equity 2.57b / Shares 129.3m; r=7.56% [WACC]; 5y FCF grow 19.68% → 2.90% )
EPS Correlation: 3.48 | EPS CAGR: 11.84% | SUE: -1.61 | # QB: 0
Revenue Correlation: 94.40 | Revenue CAGR: 8.25% | SUE: 0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.01 | Chg30d=-0.001 | Revisions Net=-4 | Analysts=6
EPS next Year (2026-12-31): EPS=0.69 | Chg30d=-0.023 | Revisions Net=-10 | Growth EPS=+8.1% | Growth Revenue=+8.3%
P/S = 0.5845
P/B = 1.0829
P/EG = 1.66
Revenue TTM = 3.29b USD
EBIT TTM = 666.6m USD
EBITDA TTM = 816.6m USD
Long Term Debt = 3.46b USD (from longTermDebt, last quarter)
Short Term Debt = 144.3m USD (from shortTermDebt, last quarter)
Debt = 3.87b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.67b USD (from netDebt column, last quarter)
Enterprise Value = 5.59b USD (1.92b + Debt 3.87b - CCE 203.4m)
Interest Coverage Ratio = 1.29 (Ebit TTM 666.6m / Interest Expense TTM 518.1m)
EV/FCF = 28.80x (Enterprise Value 5.59b / FCF TTM 194.1m)
FCF Yield = 3.47% (FCF TTM 194.1m / Enterprise Value 5.59b)
FCF Margin = 5.90% (FCF TTM 194.1m / Revenue TTM 3.29b)
Net Margin = -5.21% (Net Income TTM -171.4m / Revenue TTM 3.29b)
Gross Margin = 23.92% ((Revenue TTM 3.29b - Cost of Revenue TTM 2.50b) / Revenue TTM)
Gross Margin QoQ = 23.77% (prev 23.67%)
Tobins Q-Ratio = 0.70 (Enterprise Value 5.59b / Total Assets 7.95b)
Interest Expense / Debt = 8.66% (Interest Expense 335.1m / Debt 3.87b)
Taxrate = 17.86% (5.50m / 30.8m)
NOPAT = 547.6m (EBIT 666.6m * (1 - 17.86%))
Current Ratio = 1.88 (Total Current Assets 1.10b / Total Current Liabilities 586.0m)
Debt / Equity = 2.24 (Debt 3.87b / totalStockholderEquity, last quarter 1.73b)
Debt / EBITDA = 4.49 (Net Debt 3.67b / EBITDA 816.6m)
Debt / FCF = 18.90 (Net Debt 3.67b / FCF TTM 194.1m)
Total Stockholder Equity = 1.75b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.21% (Net Income -171.4m / Total Assets 7.95b)
RoE = -9.78% (Net Income TTM -171.4m / Total Stockholder Equity 1.75b)
RoCE = 12.79% (EBIT 666.6m / Capital Employed (Equity 1.75b + L.T.Debt 3.46b))
RoIC = 10.40% (NOPAT 547.6m / Invested Capital 5.27b)
WACC = 7.56% (E(1.92b)/V(5.79b) * Re(8.46%) + D(3.87b)/V(5.79b) * Rd(8.66%) * (1-Tc(0.18)))
Discount Rate = 8.46% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.46%
[DCF Debug] Terminal Value 82.19% ; FCFF base≈181.8m ; Y1≈215.4m ; Y5≈334.1m
Fair Price DCF = 19.87 (EV 6.24b - Net Debt 3.67b = Equity 2.57b / Shares 129.3m; r=7.56% [WACC]; 5y FCF grow 19.68% → 2.90% )
EPS Correlation: 3.48 | EPS CAGR: 11.84% | SUE: -1.61 | # QB: 0
Revenue Correlation: 94.40 | Revenue CAGR: 8.25% | SUE: 0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.01 | Chg30d=-0.001 | Revisions Net=-4 | Analysts=6
EPS next Year (2026-12-31): EPS=0.69 | Chg30d=-0.023 | Revisions Net=-10 | Growth EPS=+8.1% | Growth Revenue=+8.3%